59357-U40
Discovery® Cyano (5 µm) HPLC Columns
L × I.D. 25 cm × 4 mm, HPLC Column
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
25 cm × 4 mm
Particle size:
5 μm
Matrix active group:
cyano phase
Pore size:
180 Å
Matrix:
silica gel, high purity, spherical base material, fully porous particle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
Columna para HPLC Discovery® Cyano, 5 μm particle size, L × I.D. 25 cm × 4 mm
material
stainless steel column
Quality Level
agency
suitable for USP L10
product line
Discovery®
feature
endcapped
manufacturer/tradename
Discovery®
packaging
1 ea of
extent of labeling
4.5% Carbon loading
parameter
≤70 °C temp. range, 400 bar pressure (5801 psi)
technique(s)
HPLC: suitable, LC/MS: suitable
L × I.D.
25 cm × 4 mm
surface area
200 m2/g
surface coverage
3.5 μmol/m2
impurities
<10 ppm metals
matrix
silica gel, high purity, spherical base material, fully porous particle
matrix active group
cyano phase
particle size
5 μm
pore size
180 Å
operating pH range
2-8
application(s)
food and beverages
separation technique
hydrophilic interaction (HILIC), normal phase, reversed phase
Features and Benefits
- Baja hidrofobicidad para una rápida elución de los analíticos hidrófobos
- Forma de pico excelente y retención de los analitos fuertemente básicos
- Retención de las analitos polares
- Selectividad única
- Retención significativamente inferior a la C18 (normalmente requiere un menor porcentaje de fase orgánica móvil)
- Separaciones LC-MS estables y de bajo sangrado
- Compatible con fases orgánicas muy acuosas
Legal Information
Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under Columna para HPLC Discovery® Cyano
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Graciela B Arhancet et al.
Journal of medicinal chemistry, 53(16), 5970-5978 (2010-08-03)
A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships
Srdan Verstovsek et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 14(3), 788-796 (2008-02-05)
The discovery of an activating somatic mutation in codon 617 of the gene encoding the Janus kinase (JAK)-2 (JAK2 V617F) in patients with myeloproliferative disorders has opened new avenues for the development of targeted therapies for these malignancies. However, no
K Umekawa et al.
Japanese journal of pharmacology, 84(1), 7-15 (2000-10-24)
We describe the pharmacological characteristics of SM-19712 (4-chloro-N-[[(4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-yl)amino]carbonyl] benzenesulfonamide, monosodium salt). SM-19712 inhibited endothelin converting enzyme (ECE) solubilized from rat lung microsomes with an IC50 value of 42 nM and, at 10 - 100 microM, had no effect on other